98%
921
2 minutes
20
BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disorder. While AD diagnosis traditionally relies on clinical criteria, recent trends favor a precise biological definition. Existing biomarkers efficiently detect AD pathology but inadequately reflect the extent of cognitive impairment or disease heterogeneity. Alternative tools, such as neuroimaging and neurophysiological techniques, might better assess actual functional impairment.ObjectiveTo explore a multimodal approach-combining quantitative electroencephalography (EEG), cerebrospinal fluid (CSF), and cognitive assessment-to identify the most effective predictors of cognitive decline in AD patients.MethodsIn this observational study, 28 biologically confirmed AD patients underwent baseline evaluations including high-density EEG, CSF biomarker analysis, and cognitive assessment (Mini-Mental State Examination, MMSE). Cognitive assessment was repeated after one year. The rate of cognitive decline was calculated as monthly MMSE score change.ResultsMedian baseline age was 71.2 years. Median monthly MMSE decline was 0.25 points. Patients were classified into slow (≤0.25 MMSE/month) or fast (>0.25 MMSE/month) progressors. Fast progressors had significantly lower baseline individual alpha frequency (IAF) (6.8 Hz versus 9.1 Hz; p = 0.003), lower MMSE at one year (19 versus 24; p = 0.02), and more frequent diabetes and cardiovascular history. A multivariate regression analysis adjusted for age revealed that baseline IAF (p = 0.002), initial MMSE score (p = 0.028), and the p-tau/Aβ ratio (p < 0.01) significantly predicted monthly cognitive decline.ConclusionsCombining quantitative EEG-derived IAF, baseline cognitive status, and CSF biomarkers (p-tau/Aβ ratio) enhances prediction of AD progression. This integrated approach better captures disease heterogeneity, highlighting the need for multimodal strategies in the prognosis and management of AD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/13872877251376676 | DOI Listing |
Neurology
October 2025
Department of Radiology, Mayo Clinic, Rochester, MN.
Background And Objectives: The relationship between insomnia and cognitive decline is poorly understood. We investigated associations between chronic insomnia, longitudinal cognitive outcomes, and brain health in older adults.
Methods: From the population-based Mayo Clinic Study of Aging, we identified cognitively unimpaired older adults with or without a diagnosis of chronic insomnia who underwent annual neuropsychological assessments (z-scored global cognitive scores and cognitive status) and had quantified serial imaging outcomes (amyloid-PET burden [centiloid] and white matter hyperintensities from MRI [WMH, % of intracranial volume]).
Gerontologist
September 2025
Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, 60612United States.
Background And Objectives: Cognition may be influenced by health-related factors such as blood pressure (BP). However, variations in BP may differentially affect cognition across race. This study investigates BP and cognitive decline in older Black and White adults.
View Article and Find Full Text PDFJ Gerontol B Psychol Sci Soc Sci
September 2025
Institute of Gerontology, Wayne State University, Detroit, Michigan, United States.
Objectives: In this study, we examined the extent to which older adult social activity participation and perceptions of neighborhoods correspond with risks of cognitive impairment and no dementia (CIND) and dementia.
Methods: We predicted the risk of both CIND and dementia in a series of Cox proportional hazards analyses among older adults across a ten-year period. Utilizing data from the Health and Retirement Study (HRS, N = 15,020), we examined whether social activity participation corresponded with reduced risk of CIND and dementia, as well as whether perceptions of neighborhood conditions, social cohesion, and neighborhood disorder moderated the effects of social activity participation.
Brain
September 2025
Departamento de Fisiología, Facultad de Medicina, Universidad de Granada, 18016 Granada, Spain.
Primary coenzyme Q (CoQ) deficiency is a mitochondrial disorder with variable clinical presentation and limited response to standard CoQ10 supplementation. Recent studies suggest that 4-hydroxybenzoic acid (4-HBA), a biosynthetic precursor of CoQ, may serve as a substrate enhancement treatment in cases caused by pathogenic variants in COQ2, a gene encoding a key enzyme in CoQ biosynthesis. However, it remains unclear whether 4-HBA is required throughout life to maintain health, whether it offers advantages over CoQ10 treatment, and whether these findings are translatable to humans.
View Article and Find Full Text PDFAnn Acad Med Singap
August 2025
Dementia Research Centre (Singapore), Lee Kong Chian School of Medicine, Nanyang Technology University, Singapore.
Introduction: Interpretation and analysis of magnetic resonance imaging (MRI) scans in clinical settings comprise time-consuming visual ratings and complex neuroimage processing that require trained professionals. To combat these challenges, artificial intelligence (AI) techniques can aid clinicians in interpreting brain MRI for accurate diagnosis of neurodegenerative diseases but they require extensive validation. Thus, the aim of this study was to validate the use of AI-based AQUA (Neurophet Inc.
View Article and Find Full Text PDF